2026 Poster Presentations
P01: From Benchmark to Bench: Can Agents Survive Real-World Drug Discovery?, Presented by Pierre L. & Yijie X., Advanced Micro Devices (AMD)
P02: From Hit to Degrader: Cyclic Peptide PROTACs Restore VHL-Mediated HIF-1a Degradation in Hypoxia, Presented by Alexander M., AstraZeneca
P03: Computational Modeling of TREM2 Multimers and Design of Molecular Glues Using Molecular Modeling and Artificial Intelligence, Presented by Ismael BD., Barcelona Supercomputing Center
P04: BCover: Reaction-Aware Covalent Docking, Presented by Piero L., BEIT sp. z o.o.
P05: Unraveling PROTAC Mechanisms: From DEL Screening to Cellular Degradation Through Biophysical Profiling, Presented by Alice S., Bruker Dynamic Biosensors
P06: High-Throughput SPR Screening and Kinetic Characterization Using Carterra Vega™ with AI Binding Prediction Comparison, Presented by Andrew G., Carterra, Inc.
P07: Unleashing the Power of Spectral Shift Technology for Ultra-High-Throughput Binding Assays, Presented by Moran JW. & Johanna L., CRELUX, a WuXi AppTec Company
P08: AI-Driven Lead Optimization of Aryl Hydrocarbon Receptor (AhR) Antagonists, Presented by Shih-Chieh Y., Development Center for Biotechnology
P09: Molecular Glue Discovery Through Novel Chemical Space and AS-MS Screening, Presented by Christine K., Edelris SAS
P10: End-to-End Platform for Targeted Protein Degradation: A BRD4–CRBN Case Study, Presented by Justyna A., Enamine PL Sp. z o.o.
P11: Discovery of WEE1 Degraders: Integrating Macrocyclic PROTAC Design and High-Throughput Molecular Glue Screening, Presented by Carol A., Eurofins Discovery
P12: Accelerating Tyrosine Kinase Inhibitor Drug Discovery with Selective Late-Stage Functionalization Strategies, Presented by Matthew H., Eurofins Discovery
P13: ChemPass AI™: End-to-End Small Molecule Discovery Platform from Virtual Screening to De Novo Molecular Design, Presented by Roberto O. & Hamutal E., Evogene Ltd.
P14: Targeting Immunosuppressive Proteins with LYTACs to Enhance Immunotherapy for Head and Neck Cancer, Presented by Yuyan J., Fred Hutchinson Cancer Center
P15: ProtoBind-Diff: Protein-Conditioned Discrete Diffusion for Structure-Free Ligand Generation and Scoring, Presented by Vladimir M., Gero Pte. Ltd.
P16: Multi-Target Activity Prediction for Small Molecules, Presented by Grzegorz K., Inventro
P17: High-Throughput Surface Plasmon Resonance Screening for Small-Molecule Binders of the Sars-Cov-2 5'UTR RNA Stem-Loops (SLS), Presented by Antonino M., IRBM S.p.A.
P18: Exploration of the Biodistribution of Lipid Nanoparticles for Potential Therapeutic Delivery in the Inner Ear, Presented by Dongsik P., K-MEDI hub
P19: Small-Molecule Disruption of the LIN28A/let-7b Interaction Attenuates the Aggressive and Proinflammatory Phenotype of Rheumatoid Arthritis Fibroblast-Like Synoviocytes, Presented by Kyungrim Y., K-MEDI hub
P20: Interpretable Machine Learning for the Prediction of Phospholipid Affinity Based on IAM-HPLC Data, Presented by Krzesimir C., Medical University of Gdansk
P21: Effects of Zinc Complexes on Diabetic Wound-Derived Fibroblasts: Studies Towards an ADSC Co-Culture Model, Presented by Urszula KL., Medical University of Lodz
P22: Carbothioamidopyrazole-Based Transition Metal Complexes: Exploring Antimicrobial and Antibiofilm Potential, Presented by Ewelina N., Medical University of Lodz
P23: Targeted Protein Degraders: A Global, Open-Access, In-Stock Resource for Proximity-Induced Drug Discovery, Presented by Diana ZG., MolPort
P24: Evaluation of Physics-Based Pose Prediction and the Role of Receptor Flexibility in a Community Antiviral Blind Challenge, Presented by Asma K., Newcastle University
P25: Exploration of Cell-Permeability Features on a SARS-CoV-2 Mpro Cyclic Peptide Inhibitor, Presented by Keir P., Newcastle University
P26: Hit Identification Approaches and Hit-to-Lead Activities via D2B to Drug the JUNO/IZUMO1 Protein-Protein Interaction, a Promising Strategy for Non-Hormonal Contraception, Presented by Holger M., Nuvisan ICB GmbH
P27: Phenotypic & Targeted: Novel Approaches to Drug Discovery, Presented by Prashant S., o2h Ventures Ltd.
P28: Unlocking Challenging Targets with CETSA Across Drug Discovery, Presented by Erwin B., Pelago Bioscience AB
P29: Quantum Mechanics-Based Hydropathic Descriptors to Navigate the Isofunctional Chemical Space in Scaffold Hopping, Presented by Tiziana G., Pharmacelera
P30: CACHE 5 Challenge: Ultra-Large QM Ligand-Based Screening Identifies Potent and Structurally Novel MCHR1 Antagonists, Presented by Beth T., Pharmacelera
P31: Optimizing the Right Candidates: Live-Cell Validation of Peptides and Novel Modality Candidates Prior to MedChem, Presented by Crystal T., Portal Biotechnologies
P32: Lumit®-Based Profiling of Degrader Dynamics Reveals Signaling-Dependent, Cell Context-Specific Sensitivity to Degraders, Presented by Alissa K., Promega Corporation
P33: BRETSA: An Ultra-Sensitive, Broadly-Applicable BRET Method to Measure Target Engagement and Cellular Cooperativity Using Protein Denaturation, Presented by Ani M., Promega Corporation
P34: Trillion-Scale Macrocyclic Molecular Glue Space for Modifying or Stabilizing Specific Protein-Protein Interactions, Presented by Dmitry G. & Anna Z., Pyxis Discovery
P35: Discovery of Novel TEAD Inhibitors Using Time-Resolved Transcriptomics, Presented by Pascal B., QUANTRO Therapeutics GmbH
P36: Oral Absorption Prediction via Hybrid Modeling: Integrating Physicochemical Simulation and Machine Learning, Presented by Katsutaka Y., Shionogi & Co., Ltd.
P37: SAFR: Enabling Fragment-Based Drug Discovery with a Synthetic Binding Pose Data Set, Presented by Joan CM., Universitat de Girona
P38: Lessons from a Fragment-Based Campaign Against Fbw7: Challenges in Validating Weak Ligands for a Flexible E3 Ligase, Presented by Roger CM., University of Barcelona
P39: The Quest for Small-Molecule PROTACs Targeting ß-Catenin, Presented by Serena F., University of Barcelona & University of Torino
P40: Targeted Degradation of Pin1 by Molecular Crowbars-Like Compounds, Presented by Giulia A., University of California, Riverside
P41: Targeting the EphA4-Ephrin Protein-Protein Interactions with Peptide Mimetics, Presented by Emma A., University of California, Riverside
P42: Targeting Metastases and Targeted Delivery of Chemo- or Radiotherapy with the EphaA2 Targeting Agent Targefrin, Presented by Carlo B., University of California, Riverside
P43: Histidine-Covalent Cyclic Aryl-Fluorosulfate Peptides Targeting KRAS Mutants, Presented by Anne Marie P., University of California, Riverside
P44: Novel Lysine- or Histidine-Covalent Chemotypes Targeting hMcl-1, Presented by Daniele R., University of California, Riverside
P45: A Function-First DEL Selection Method for the Discovery of New PROTACs and E3 Ligase Ligands, Presented by Cen H., University of Hong Kong
P46: PROTAC Builder Ecosystem: An Integrated Computational Platform for Structure-Guided Degrader Design and Evaluation, Presented by Joseph S., University of Miami
P47: Chemical Strategies to Exploit the ClpC:ClpP Protein Degradation Machinery in Gram-Positive Bacteria, Presented by Siobhan B., University of the Western Cape
P48: A Diversified Covalent-Fragment Collection for Drug Discovery. The Vernalis Covalent Fragment Library – From Design to Screening, Presented by Ben D., Vernalis R&D Ltd.
P49: DELs in Cells: Direct Discovery of p53–MDM2 PPI Inhibitors, Presented by Leif L., Vipergen ApS
P50: Linkerology & ADME Optimisation of BETAC-1, a Novel BRD4 Bifunctional Degrader, Presented by Robin W., Viva Biotech
P51: Integrating DELs, Minimalist Med Chem Linkers and D2B for Target Binding, Presented by Bing X., Viva Biotech
P52: From Library to Lead: Unlocking Peptide Therapeutics with DNA-Encoded and Display Platforms, Presented by Rhys T, WuXi AppTec
P53: DEL Data-Driven Discovery of Brachyury (TBXT) Ligand Toward Chordoma Therapeutics, Presented by Matt C. & Jordan P., X-Chem, Inc.
P54: Agentic AI for Autonomous Discovery, Presented by Bence B., XtalPi, Inc.